OTCM
YUHNF
Market cap3.29bUSD
, Last price
Name
Yuhan Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||